Drug Profile


Alternative Names: BAY-94-8862

Latest Information Update: 25 Mar 2017

Price : $50

At a glance

  • Originator Bayer HealthCare Pharmaceuticals
  • Class Amides; Heart failure therapies; Naphthyridines; Nitriles; Small molecules
  • Mechanism of Action Mineralocorticoid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Chronic heart failure; Diabetic nephropathies
  • Phase I Renal failure

Most Recent Events

  • 01 Mar 2017 Bayer completes a phase I trial in Renal failure (In volunteers) in Germany (PO, Suspension) (EudraCT2016-002813-24)
  • 04 Nov 2016 Bayer plans a phase I trial in Healthy volunteers in Germany (NCT02957396)
  • 03 Nov 2016 Bayer plans a phase I trial in Healthy volunteers in Germany (NCT02956109)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top